• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).

作者信息

Singh Awadhesh Kumar, Gupta Ritesh, Misra Anoop

出版信息

Diabetes Metab Syndr. 2020 Sep-Oct;14(5):729. doi: 10.1016/j.dsx.2020.05.030. Epub 2020 May 23.

DOI:10.1016/j.dsx.2020.05.030
PMID:32473904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7244409/
Abstract
摘要

相似文献

1
Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).对马哈詹和高尔针对文章《COVID-19中的合并症：高血压队列的结局以及与肾素血管紧张素系统阻滞剂的争议》（辛格等人著）的来信的回复
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):729. doi: 10.1016/j.dsx.2020.05.030. Epub 2020 May 23.
2
Letter in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.).针对文章《COVID-19中的合并症：高血压队列的结局及肾素血管紧张素系统阻滞剂相关争议》（辛格等人著）的回应信
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):723-724. doi: 10.1016/j.dsx.2020.05.029. Epub 2020 May 23.
3
Reply to the letter of Singh and Singh in response to the article: "Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis" (Kumar et al.).对辛格和辛格针对文章《糖尿病与2019冠状病毒病的死亡率及严重程度相关吗？一项荟萃分析》（库马尔等人著）所写信件的回复
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1147-1148. doi: 10.1016/j.dsx.2020.07.002. Epub 2020 Jul 8.
4
Letter in response to letter to the editor by Singh and Dhibar regarding the article "COVID-19: From bench to bedside" (Singh et al.).对辛格和迪巴尔就文章《COVID-19：从实验室到临床》（辛格等人著）致编辑的信的回复信。
Diabetes Metab Syndr. 2020 Sep-Oct;14(5):865. doi: 10.1016/j.dsx.2020.06.012. Epub 2020 Jun 12.
5
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections.对近期有关血管紧张素转换酶2（ACE2）和肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染相关性的评论的回应
Drug Dev Res. 2020 Sep;81(6):643-646. doi: 10.1002/ddr.21672. Epub 2020 Apr 17.
6
Reply to Letter to the Editor: "Don't judge too RAShly: the multifaceted role of the renin-angiotensin system and its therapeutic potential in COVID-19".致编辑信件的回复：“勿轻率评判：肾素 - 血管紧张素系统的多面作用及其在 COVID - 19 中的治疗潜力”
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L1029-L1030. doi: 10.1152/ajplung.00133.2020.
7
Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?肾素-血管紧张素-醛固酮系统抑制剂对2019冠状病毒病死亡率的影响：血管紧张素转换酶2的下一步是什么？
Clin Infect Dis. 2020 Nov 19;71(16):2129-2131. doi: 10.1093/cid/ciaa627.
8
Letter to the Editor - Circulating plasma levels of angiotensin II and aldosterone in patients with coronavirus disease 2019 (COVID-19): A preliminary report.致编辑的信——2019冠状病毒病（COVID-19）患者循环血浆中血管紧张素II和醛固酮水平：初步报告
Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):702-703. doi: 10.1016/j.pcad.2020.07.006. Epub 2020 Jul 10.
9
[Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19].
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jul 24;48(7):565-566. doi: 10.3760/cma.j.cn112148-20200329-00262.
10
The Renin-Angiotensin system and SARS-CoV-2 infection: A role for the ACE2 receptor?肾素-血管紧张素系统与新型冠状病毒2019感染：血管紧张素转换酶2受体的作用？
J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926911. doi: 10.1177/1470320320926911.

本文引用的文献

1
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者：法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
2
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
3
Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers.新型冠状病毒肺炎的合并症：高血压患者队列的结局以及肾素-血管紧张素系统阻滞剂引发的争议
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):283-287. doi: 10.1016/j.dsx.2020.03.016. Epub 2020 Apr 9.
4
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
5
ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis.血管紧张素转换酶2（ACE2）的X射线结构揭示了一种对抑制剂结合和催化作用很重要的大幅度铰链弯曲运动。
J Biol Chem. 2004 Apr 23;279(17):17996-8007. doi: 10.1074/jbc.M311191200. Epub 2004 Jan 30.